Treatment of diabetes with milk protein hydrolysate

Abstract

A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum.

What is claimed is:  
     
         1 . A method of treatment of diabetes or syndrome X which comprises administering to a subject in need of such treatment an effective amount of a milk protein hydrolysate that is capable of inducing release of GLP-1 in the subject in an amount sufficient to improve glucose metabolism in the subject or to control glycemic response in the subject.  
     
     
         2 . The method of  claim 1 , wherein the milk protein hydrolysate is a caseinoglycomacropeptide, or a mimetic, homologue or fragment thereof.  
     
     
         3 . The method of  claim 1 , wherein the milk protein hydrolysate is sweet whey, acid whey, a caseinoglycomacropeptide or a mixture thereof.  
     
     
         4 . The method of  claim 1 , wherein the milk protein hydrolysate is a calcium or sodium salt of a caseinoglycomacropeptide or a mixture thereof.  
     
     
         5 . The method of  claim 1 , wherein the hydrolysate is provided in the form of a food product, a food supplement or a nutritional supplement.  
     
     
         6 . The method of  claim 5 , wherein the hydrolysate is present in an amount of about 0.01% to about 10% by weight dry matter the food product, food supplement, or nutritional supplement.  
     
     
         7 . The method of  claim 1 , wherein the hydrolysate is provided in a composition that includes one or more of a fat, a carbohydrate, a dietary fiber, an emulsion, vitamins or minerals.  
     
     
         8 . The method of  claim 7 , wherein the hydrolysate is provided in a composition that has a powder or liquid form.  
     
     
         9 . The method of  claim 1 , wherein the hydrolysate is included in a yogurt, a confectionery, a cereal or a beverage.  
     
     
         10 . A method for manufacturing a composition for the treatment or prevention of diabetes or syndrome X, which comprises formulating the composition to induce release of GLP-1, in a bioavailable form, in a subject when administered thereto, by incorporating a milk protein hydrolysate or compound including a milk protein hydrolysate in the composition.  
     
     
         11 . A method for inducing release of GLP-1 in a subject by administering thereto a milk protein hydrolysate or compound including a milk protein hydrolysate in an amount sufficient to cause secretion of GLP-1 in the subject.  
     
     
         12 . A model for the study of proglucagon gene expression and GLP-1 production by humans, which includes the use of a cell line derived from an adenocarcinoma of human caecum.  
     
     
         13 . A model for the study of proglucagon gene expression and GLP-1production by humans, which includes the use of a cell line derived from anadenocarcinoma of human caecum.  
     
     
         14 . A method for assessing proglucagon gene expression and GLP-1 release in humans which comprises utilizing a cell line derived from an adenocarcinoma of human caecum.  
     
     
         15 . The method of  claim 14 , wherein the cell line is NCI-H716 cell line having the ATCC number CCL-251